News

Eating pros vs those with eating disorders: what’s the difference?

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

A traumatic brain injury sustained earlier in adult life is likely to interact with normal aging processes. Learn more here.

What can we learn from artists’ memoirs?

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

Where do we draw the line on level of impairment for our presidential candidates?

This celebration of the creativity of the arts comes at a time when the arts have been cut in school education and in psychiatry.

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic.

"A single gem has throbbed in my chest my whole life, even though, even though this is my second heart..."

How can we protect the mental health of our country?

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

Mental health clinicians can help empower patients via tools like diet, including the MIND Diet.

This book seeks to reduce the stigma surrounding teen pregnancy.

Enter your email to see the results of our polls on social media usage amongst mental health clinicians!

Psychiatrists and mental health clinicians: a social determinant of health.

Celebrating 4 years of Psychiatry & Society!

With art we build what poverty destroys.

Are there parts of the movie “It Ends With Us” that could have suicide protective effects for viewers?

New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.

Learn more about the latest viral substance abuse trend.

Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.

Reports of suicidality with GLP-1RA antiobesity medication are supported by analysis of WHO data, but no association is found in large population cohort study or analysis of clinical trials.

A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.

Saturday was the International Day of Peace.

Rural areas suffer from a severe shortage of mental health professionals. How can nurse practitioners help?

How comfortable do you feel in your knowledge of this type of treatment?

Enter your email to check out this complicated case!

Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.